A previous phase II trial (Okayama Lung Cancer Study Group Trial 1001) showed that gefitinib in combination with bevacizumab as first-line therapy for advanced EGFR-mutated NSCLC resulted in a median PFS of 14.4 months [16]. Here, EGFR is linked to lung cancer.